DDInter1581 DDInter1662
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia
Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as [Citalopram] and [Fluoxetine]. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects. Several weeks of therapy with sertraline may be required before beneficial effects are noticed. Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which frequently cause high levels of drowsiness, dizziness, blurred vision, and other undesirable effects.[A1846,A187075,T28]
Repaglinide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sertraline
Repaglinide {u} (Compound) causes {v} (Side Effect) Anaphylactic shock
Anaphylactic shock {u} (Side Effect) is caused by {v} (Compound) Sertraline
Repaglinide {u} (Compound) causes {v} (Side Effect) Eye disorder
Eye disorder {u} (Side Effect) is caused by {v} (Compound) Maprotiline
Maprotiline {u} (Compound) resembles {v} (Compound) Sertraline
Repaglinide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is associated with {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sertraline
Repaglinide {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) regulates {v} (Gene) CTSD
CTSD {u} (Gene) is upregulated by {v} (Compound) Sertraline
Repaglinide {u} (Compound) binds {v} (Gene) KCNJ11
KCNJ11 {u} (Gene) regulates {v} (Gene) VAPB
VAPB {u} (Gene) is downregulated by {v} (Compound) Sertraline
Repaglinide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is associated with {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Sertraline
Repaglinide {u} (Compound) downregulates {v} (Gene) DNMT3A
DNMT3A {u} (Gene) interacts with {v} (Gene) EED
EED {u} (Gene) is downregulated by {v} (Compound) Sertraline
Repaglinide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Amcinonide {u} (Compound) upregulates {v} (Gene) MCOLN1
MCOLN1 {u} (Gene) is upregulated by {v} (Compound) Sertraline
Repaglinide {u} (Compound) downregulates {v} (Gene) DNMT3A
DNMT3A {u} (Gene) regulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is upregulated by {v} (Compound) Sertraline
Repaglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sertraline (Compound)
Repaglinide (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Sertraline (Compound)
Repaglinide (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Maprotiline (Compound) and Maprotiline (Compound) resembles Sertraline (Compound)
Repaglinide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is associated with CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sertraline (Compound)
Repaglinide (Compound) binds ALB (Gene) and ALB (Gene) regulates CTSD (Gene) and CTSD (Gene) is upregulated by Sertraline (Compound)
Repaglinide (Compound) binds KCNJ11 (Gene) and KCNJ11 (Gene) regulates VAPB (Gene) and VAPB (Gene) is downregulated by Sertraline (Compound)
Repaglinide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is associated with HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Sertraline (Compound)
Repaglinide (Compound) downregulates DNMT3A (Gene) and DNMT3A (Gene) interacts with EED (Gene) and EED (Gene) is downregulated by Sertraline (Compound)
Repaglinide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Sertraline (Compound)
Repaglinide (Compound) downregulates DNMT3A (Gene) and DNMT3A (Gene) regulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Sertraline (Compound)